SPX4,073.79-6.32 -0.15%
DIA344.00-2.15 -0.62%
IXIC11,463.53-4.47 -0.04%

Surrozen Pauses Early-Stage Ulcerative Colitis Study Due To Liver Associated Adverse Events

Benzinga · 11/16/2022 06:43
  • Tucked in its Q3 earnings release on Monday afternoon, Surrozen Inc (NASDAQ:SRZN) voluntarily paused enrollment in the single ascending dose (SAD) portion of its Phase 1 trial evaluating SZN-1326 in healthy volunteers following the observation of treatment-related adverse events. 
  • SZN-1326 is a Wnt mimetic bi-specific antibody that selectively activates the Wnt pathway and is in development for ulcerative colitis.
  • Several subjects experienced asymptomatic liver transaminase elevations (elevated liver enzymes), including three subjects with grade 3 ALT and AST elevations. 
  • Related: Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate.
  • Elevated levels of either of these enzymes are potential indicators of liver damage or liver disease.
  • There were no corresponding increases in total bilirubin nor any changes in liver function markers such as coagulation markers or albumin. 
  • No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects. 
  • No serious adverse events were observed during the study. 
  • Price Action: SRZN shares closed 30.2% lower at $1.25 on Tuesday.